226 related articles for article (PubMed ID: 31929402)
21. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Katrak S; Gasasira A; Arinaitwe E; Kakuru A; Wanzira H; Bigira V; Sandison TG; Homsy J; Tappero JW; Kamya MR; Dorsey G
Malar J; 2009 Nov; 8():272. PubMed ID: 19948038
[TBL] [Abstract][Full Text] [Related]
23. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Whalen ME; Kajubi R; Goodwin J; Orukan F; Colt M; Huang L; Richards K; Wang K; Li F; Mwebaza N; Aweeka FT; Parikh S
Clin Infect Dis; 2023 Feb; 76(3):443-452. PubMed ID: 36130191
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
Sevene E; Banda CG; Mukaka M; Maculuve S; Macuacua S; Vala A; Piqueras M; Kalilani-Phiri L; Mallewa J; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
Malar J; 2019 Aug; 18(1):277. PubMed ID: 31429785
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.
Lohy Das J; Rulisa S; de Vries PJ; Mens PF; Kaligirwa N; Agaba S; Tarning J; Karlsson MO; Dorlo TPC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061282
[TBL] [Abstract][Full Text] [Related]
27. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Mosha D; Guidi M; Mwingira F; Abdulla S; Mercier T; Decosterd LA; Csajka C; Genton B
Antimicrob Agents Chemother; 2014 Aug; 58(8):4583-92. PubMed ID: 24867986
[TBL] [Abstract][Full Text] [Related]
29. Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.
Nyangulu W; Mungwira RG; Divala TH; Nampota-Nkomba N; Nyirenda OM; Buchwald AG; Miller J; Earland DE; Adams M; Plowe CV; Taylor TE; Mallewa JE; van Oosterhout JJ; Parikh S; Laurens MB; Laufer MK;
Malar J; 2023 Jan; 22(1):32. PubMed ID: 36707795
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
32. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.
Kajubi R; Huang L; Were M; Kiconco S; Li F; Marzan F; Gingrich D; Nyunt MM; Ssebuliba J; Mwebaza N; Aweeka FT; Parikh S
Open Forum Infect Dis; 2016 Oct; 3(4):ofw217. PubMed ID: 28018925
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa.
Onyamboko MA; Hoglund RM; Lee SJ; Kabedi C; Kayembe D; Badjanga BB; Turner GDH; Jackson NV; Tarning J; McGready R; Nosten F; White NJ; Day NPJ; Fanello C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818818
[TBL] [Abstract][Full Text] [Related]
34. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
[TBL] [Abstract][Full Text] [Related]
35. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.
McGready R; Tan SO; Ashley EA; Pimanpanarak M; Viladpai-Nguen J; Phaiphun L; Wüstefeld K; Barends M; Laochan N; Keereecharoen L; Lindegardh N; Singhasivanon P; White NJ; Nosten F
PLoS Med; 2008 Dec; 5(12):e253. PubMed ID: 19265453
[TBL] [Abstract][Full Text] [Related]
36. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Usman SO; Oreagba IA; Kadri MR; Adewumi OO; Akinyede A; Agbaje EO; Abideen G; Busari AA; Hassan OO; Akinleye MO; Akanmu AS
Eur J Clin Pharmacol; 2021 Sep; 77(9):1341-1348. PubMed ID: 33755736
[TBL] [Abstract][Full Text] [Related]
38. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
40. Comparison on simultaneous caillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda.
Lehane A; Were M; Wade M; Hamadu M; Cahill M; Kiconco S; Kajubi R; Aweeka F; Mwebaza N; Li F; Parikh S
BMC Infect Dis; 2019 Jun; 19(1):559. PubMed ID: 31242863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
